# Saccharomyces cerevisiae UFMG 905

**Canonical URL:** https://ingredients.hermeticasuperfoods.com/ingredients/saccharomyces-cerevisiae-ufmg-905
**Data Source:** Hermetica Superfoods Ingredient Encyclopedia
**Updated:** 2026-04-03
**Evidence Score:** 2 / 10
**Category:** Fermented/Probiotic
**Also Known As:** S. cerevisiae UFMG 905, UFMG 905 strain, Saccharomyces cerevisiae strain UFMG 905, UFMG-905, Probiotic yeast UFMG 905, Baker's yeast strain UFMG 905

## Overview

Saccharomyces cerevisiae UFMG 905 is a [probiotic](/ingredients/condition/gut-health) yeast strain whose cell wall components, including [beta-glucan](/ingredients/condition/immune-support)s and mannoproteins, modulate immune responses via pattern recognition receptors. It has shown anti-inflammatory and anti-allergic effects in preclinical models by suppressing myeloperoxidase activity and reducing [pro-inflammatory cytokine](/ingredients/condition/inflammation) signaling.

## Health Benefits

• May reduce intestinal inflammation markers in preclinical colitis models by decreasing myeloperoxidase activity and [pro-inflammatory cytokine](/ingredients/condition/inflammation)s (animal evidence only, PMID: 26322540)
• Potentially supports respiratory health by reducing bronchial hyperresponsiveness and eosinophils at 10⁹ CFU/mL doses (preliminary mouse studies, PMID: 36445686)
• Could improve intestinal barrier function by reducing permeability and bacterial translocation while increasing IL-10 (preclinical evidence, PMID: 20437166)
• May modulate immune responses by increasing regulatory T cells and anti-inflammatory fatty acids like dihomo-γ-linolenic acid (animal models only, PMC12918630)
• Potentially attenuates food allergy-related tissue injury and IL-17 levels in dose-dependent manner (preliminary evidence from mice, PMID: 32264688)

## Mechanism of Action

Saccharomyces cerevisiae UFMG 905 cell wall beta-1,3/1,6-glucans engage Dectin-1 receptors on innate immune cells, suppressing NF-κB-driven transcription of TNF-α, IL-6, and IL-1β while promoting regulatory [cytokine](/ingredients/condition/inflammation) profiles. In colitis models, the strain reduces myeloperoxidase (MPO) activity in colonic tissue, indicating attenuation of neutrophil infiltration. In respiratory models, it appears to shift Th2-skewed immune responses, reducing eosinophil recruitment and IL-5 signaling at doses of approximately 10⁹ CFU/mL.

## Clinical Summary

Current evidence for Saccharomyces cerevisiae UFMG 905 derives exclusively from preclinical animal studies, with no published human clinical trials identified as of 2024. In murine colitis models (PMID: 26322540), oral administration significantly decreased colonic MPO activity and [pro-inflammatory cytokine](/ingredients/condition/inflammation)s compared to controls. Respiratory studies in animal models demonstrated reductions in bronchial hyperresponsiveness and eosinophil counts at a dose of 10⁹ CFU/mL. Evidence strength is rated low; human trials are required before efficacy claims can be substantiated.

## Nutritional Profile

Saccharomyces cerevisiae UFMG 905 is a yeast strain with a nutritional composition typical of Saccharomyces cerevisiae species, though strain-specific quantitative data remains limited in published literature. As a yeast-based organism, the cell biomass contains approximately 40-50% protein by dry weight, rich in all essential amino acids including lysine and threonine. Carbohydrates constitute approximately 30-40% of dry weight, primarily as beta-glucans (notably β-1,3/1,6-glucan, estimated 10-20% dry weight) and mannan polysaccharides forming the cell wall; these beta-glucans are considered key [immunomodulatory](/ingredients/condition/immune-support) bioactive compounds. Lipid content is approximately 5-10% dry weight, including ergosterol (a precursor to vitamin D2). B-vitamin content is characteristic of S. cerevisiae: thiamine (B1) ~1-2 mg/100g dry weight, riboflavin (B2) ~4-6 mg/100g, niacin (B3) ~30-50 mg/100g, pantothenic acid (B5) ~10-15 mg/100g, pyridoxine (B6) ~3-5 mg/100g, and folate ~1-2 mg/100g. Minerals present include zinc (~5-10 mg/100g), selenium (variable, strain-dependent), chromium, iron (~2-5 mg/100g), and potassium (~1500-2000 mg/100g). As a [probiotic](/ingredients/condition/gut-health)/fermented ingredient administered in CFU-based doses (studies reference 10⁹ CFU/mL), the nutritional contribution per dose is minimal; bioactive effects are primarily mediated through cell wall components (beta-glucans, mannoproteins) and metabolic byproducts including short-chain organic acids. Bioavailability of minerals may be reduced by phytate content inherent to yeast cell walls; however, cell wall beta-glucans and mannoproteins retain biological activity in the gastrointestinal tract, interacting with Dectin-1 and Toll-like receptors on immune cells. No strain-specific UFMG 905 nutritional quantification has been independently published as of available literature.

## Dosage & Preparation

In animal studies, oral doses ranged from 10⁷ to 10⁹ CFU/mL daily or alternate-day, with highest efficacy at 10⁹ CFU/mL for respiratory [inflammation](/ingredients/condition/inflammation). Viable yeast showed superior effects compared to heat-killed or supernatant forms. No human dosing data is available. Consult a healthcare provider before starting any new supplement.

## Safety & Drug Interactions

As a Saccharomyces cerevisiae-derived strain, UFMG 905 is generally expected to carry the safety profile typical of [probiotic](/ingredients/condition/gut-health) yeasts, but no dedicated human safety studies have been published for this specific strain. Individuals with yeast allergies, Crohn's disease with anti-Saccharomyces cerevisiae antibodies (ASCA), or severely immunocompromised status should exercise caution, as fungal probiotic strains carry a rare risk of fungemia in these populations. No formal drug interaction data exist for UFMG 905, though concurrent antifungal medications such as fluconazole would likely reduce its viability and efficacy. Pregnant or breastfeeding individuals should avoid use until human safety data are available.

## Scientific Research

All available evidence for S. cerevisiae UFMG 905 comes exclusively from murine (mouse) models with no human clinical trials, RCTs, or meta-analyses identified. Key preclinical studies include DSS-induced colitis models (PMID: 26322540), ovalbumin-induced asthma models (PMC12918630, PMID: 36445686), and intestinal obstruction models (PMID: 20437166) using groups of 4-6 Balb/c mice.

## Historical & Cultural Context

S. cerevisiae UFMG 905 has no documented traditional medicinal use or presence in historical systems like Ayurveda, TCM, or folk medicine. It is strictly a research-isolated strain developed at UFMG for scientific investigation of [probiotic](/ingredients/condition/gut-health) properties.

## Synergistic Combinations

Other Saccharomyces strains, Lactobacillus species, Bifidobacterium species, [prebiotic](/ingredients/condition/gut-health) fibers, vitamin D

## Frequently Asked Questions

### What is Saccharomyces cerevisiae UFMG 905 and how does it differ from brewer's yeast?

Saccharomyces cerevisiae UFMG 905 is a specific probiotic strain isolated and characterized at the Universidade Federal de Minas Gerais in Brazil, distinct from commercial brewer's or baker's yeast in its immunomodulatory properties and documented anti-inflammatory activity. Unlike generic S. cerevisiae strains, UFMG 905 has been specifically studied for its effects on gut and respiratory inflammation in preclinical models. Strain-specific characteristics, including cell wall composition and beta-glucan architecture, likely account for its unique biological activity.

### What dose of Saccharomyces cerevisiae UFMG 905 was used in studies?

Preclinical respiratory studies utilized a concentration of approximately 10⁹ CFU/mL, which is a common probiotic-range dose consistent with other Saccharomyces-based interventions. Colitis model studies (PMID: 26322540) also employed oral administration protocols, though exact CFU dosing details vary by protocol. No human dose-ranging or pharmacokinetic studies have been conducted, so an evidence-based human dosage recommendation cannot currently be established.

### Can Saccharomyces cerevisiae UFMG 905 help with inflammatory bowel disease?

Animal studies suggest UFMG 905 may reduce markers of intestinal inflammation, specifically by lowering colonic myeloperoxidase activity and suppressing TNF-α and IL-1β in induced colitis models (PMID: 26322540). However, no human clinical trials in IBD patients have been conducted for this strain, making it premature to recommend it as a therapeutic intervention. Individuals with Crohn's disease should note that elevated ASCA titers are common in that condition, which may indicate an adverse immunological response to Saccharomyces strains.

### Is Saccharomyces cerevisiae UFMG 905 safe for people with yeast allergies or immunodeficiency?

People with known yeast or mold allergies should avoid UFMG 905 due to potential cross-reactivity with Saccharomyces cell wall antigens including mannoproteins. Immunocompromised individuals, including those on chemotherapy, organ transplant recipients, or those with HIV/AIDS, face a rare but documented risk of Saccharomyces fungemia from probiotic yeast supplementation and should consult a physician before use. No strain-specific safety studies in these populations have been published for UFMG 905.

### How does Saccharomyces cerevisiae UFMG 905 compare to Saccharomyces boulardii for gut health?

Saccharomyces boulardii is the most clinically studied probiotic yeast, with over 80 human randomized controlled trials supporting its use in antibiotic-associated diarrhea and C. difficile infection, while UFMG 905 currently has only preclinical data. Both strains modulate intestinal immunity through beta-glucan-Dectin-1 interactions and cytokine regulation, but S. boulardii additionally produces a 54 kDa protease that cleaves C. difficile toxins, a property not yet characterized in UFMG 905. Until human trials are completed, UFMG 905 cannot be considered a clinical equivalent to S. boulardii.

### What does the research evidence show about Saccharomyces cerevisiae UFMG 905's effectiveness?

Current evidence for Saccharomyces cerevisiae UFMG 905 is limited to preclinical and animal studies, with most research conducted in mouse colitis models showing reductions in inflammatory markers like myeloperoxidase and pro-inflammatory cytokines. Preliminary respiratory studies in mice suggest potential benefits for bronchial hyperresponsiveness at 10⁹ CFU/mL doses, but human clinical trials are lacking. The strain shows promise for gut barrier function support, though these findings require confirmation in human subjects before drawing definitive conclusions.

### Who should consider taking Saccharomyces cerevisiae UFMG 905 supplementation?

Based on available evidence, individuals with inflammatory conditions affecting the gut or respiratory system may be potential candidates, though human research is limited. People with compromised immune systems or those with yeast hypersensitivity should avoid this strain or consult a healthcare provider first. Current data does not establish clear populations that definitively benefit, making professional medical guidance essential before use.

### How does Saccharomyces cerevisiae UFMG 905 work to reduce inflammation?

In animal models, this strain appears to decrease intestinal inflammation by lowering myeloperoxidase activity and reducing pro-inflammatory cytokine production within the gut. The mechanism likely involves interaction with intestinal barrier integrity, though the specific pathways by which UFMG 905 achieves these effects in humans remain unclear. Additional research is needed to characterize its immunomodulatory mechanisms in clinical settings.

---

*Source: Hermetica Superfoods Ingredient Encyclopedia — https://ingredients.hermeticasuperfoods.com*
*License: CC BY-NC-SA 4.0 — Attribution required. Commercial use: admin@hermeticasuperfoods.com*